UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Clinical trials for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 trials appear
Sign up with your email to follow new studies for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Second dose of targeted radiation may outperform standard drugs for stubborn gut tumors
Disease control Recruiting nowThis study is for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be surgically removed. It compares retreatment with a targeted radiation therapy (177Lu-DOTATATE) to standard drugs (everolimus, sunitinib, or cabozantinib) to see whi…
Matched conditions: UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Double radiation attack: new hope for Hard-to-Treat gut tumors?
Disease control Recruiting nowThis early-phase study tests whether adding a precise, high-dose external radiation treatment (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and works better for people with large, inoperable neuroendocrine tumors of the digestive system. About 15 adul…
Matched conditions: UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 20, 2026 11:57 UTC